Clinical Trials Logo

Eclampsia Preeclampsia clinical trials

View clinical trials related to Eclampsia Preeclampsia.

Filter by:
  • None
  • Page 1

NCT ID: NCT05199558 Not yet recruiting - Clinical trials for Eclampsia Preeclampsia

Improved Characterisation of Eclampsia

Start date: March 2022
Phase:
Study type: Observational

Eclampsia is a serious pregnancy complication.In our study we aim to characterize the clinical signs and symptoms that occur prior to the onset of eclampsia in a prospectively collected cohort.And Compare these characteristics to women with preeclampsia and healthy normal pregnancies to identify which features represent a unique clinical signature for eclampsia to form a simple predictive algorithm .

NCT ID: NCT03856307 Completed - Clinical trials for Obstetric Complication

Reliability of Simple Sonographic Findings Acquired With Hand-held Apparatuses to Inform Obstetric Diagnosis

Start date: March 1, 2019
Phase:
Study type: Observational [Patient Registry]

the study aims to assess the reliability of ultrasound findings measured by hand held ultrasound probes used by operators with variable experience in a low resource hospital.

NCT ID: NCT03674606 Completed - Pre-Eclampsia Clinical Trials

Trial of Early Screening Test for Pre-eclampsia and Growth Restriction

TEST
Start date: February 1, 2014
Phase: Phase 4
Study type: Interventional

A study of aspirin use in pregnancy to prevent high blood pressure and growth restriction of the fetus

NCT ID: NCT03143647 Completed - Clinical trials for Eclampsia Preeclampsia

Magnesium and Platelet Function Testing

MgCedVD
Start date: June 9, 2017
Phase:
Study type: Observational [Patient Registry]

Magnesium has built up the reputation of a 'natural calcium antagonist'. However, the exact effect of magnesium on coagulation and more specifically on platelet function is still disputed. An important discrepancy between in vivo and in vitro studies exists. Magnesium has thus been reported to antagonize platelets in some studies, and to stimulate platelets in other studies. Current evidence seems to point in the direction of a general antagonization of aggregation and coagulation. Intravenous magnesium is often administered in pre-eclampsia as seizure prophylaxis. Therapeutic regimens usually consist of an intravenously administered loading dose (2-3 grams) and a maintenance infusion, targeting a plasma level of 2-3 mmol/L. Therapeutic drug monitoring is needed, as magnesium toxicity is an important concern.